The hypoxic microenvironment upgrades stem-like properties of ovarian cancer cells.
BACKGROUND
To study whether hypoxia influences the stem-like properties of ovarian cancer cells and their biological behavior under hypoxia.


METHODS
Ovarian cancer cell lines ES-2 and OVCAR-3 were cultivated in different oxygen tensions for proliferation, cell cycling and invasion analyses. The clonogenic potential of cells was examined by colony formation and sphere formation assays. Stem cell surface markers, SP and CD44bright and CD44dim cells were analyzed by flow cytometry. Protein expression of HIF-1α, HIF-2α, Ot3/4 and Sox2 were investigated by Western blotting.


RESULTS
Both cell lines cultivated at hypoxic condition grew relatively slowly with extended G0/G1 phase. However, if the cells were pre-treated under 1% O2 for 48 hrs before brought back to normoxia, the cells showed significantly higher proliferation rate with higher infiltration capability, and significant more colonies and spheres, in comparison to the cells always cultivated under normoxia. CD44bright cells expressed significantly higher levels of Oct3/4 and Sox2 than the CD44dim cells and formed significantly more clones and spheres examined in vitro. Hypoxic treatment of the cells resulted in stronger CD44 expression in both cell lines, and stronger CD133 expression in the OVCAR-3 cell line. In parallel with these findings, significantly increased number of side population (SP) cells and up-regulated expression of Oct3/4 and Sox2 in both ES-2 and OVCAR-3 cell lines were observed.


CONCLUSIONS
We conclude that ovarian cancer cells survive hypoxia by upgrading their stem-like properties through up-regulation of stemness-related factors and behave more aggressively when brought back to higher oxygen environment.
Departments of Pathology, the Norwegian Radium Hospital, Oslo University Hospital, University of Oslo, Montebello, Oslo, Norway.
Dongming
D
Liang
Yuanyuan
Y
Ma
Jian
J
Liu
Claes Goran
CG
Trope
Ruth
R
Holm
Jahn M
JM
Nesland
Zhenhe
Z
Suo
D000071916:AC133 Antigen; D015703:Antigens, CD / Q000378:metabolism; D002453:Cell Cycle; D015687:Cell Hypoxia; D045744:Cell Line, Tumor; D049109:Cell Proliferation; D005260:Female; D006023:Glycoproteins / Q000378:metabolism; D006801:Humans; D018960:Hyaluronan Receptors / Q000378:metabolism; D014411:Neoplastic Stem Cells / Q000378:metabolism*; D010051:Ovarian Neoplasms / Q000378:metabolism*; D010455:Peptides / Q000378:metabolism; D010641:Phenotype; D058985:Side-Population Cells / Q000378:metabolism; D014157:Transcription Factors / Q000378:metabolism; D059016:Tumor Microenvironment
D000071916:AC133 Antigen; D015703:Antigens, CD; D006023:Glycoproteins; D018960:Hyaluronan Receptors; C000606023:PROM1 protein, human; D010455:Peptides; D014157:Transcription Factors